4277 related articles for article (PubMed ID: 25904081)
21. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease.
Iannaccone S; Cerami C; Alessio M; Garibotto V; Panzacchi A; Olivieri S; Gelsomino G; Moresco RM; Perani D
Parkinsonism Relat Disord; 2013 Jan; 19(1):47-52. PubMed ID: 22841687
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathological features of Parkinson's disease.
Schneider SA; Obeso JA
Curr Top Behav Neurosci; 2015; 22():205-20. PubMed ID: 24850081
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease.
Wolters EC; Calne DB
CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
[TBL] [Abstract][Full Text] [Related]
24. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
25. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
Hodaie M; Neimat JS; Lozano AM
Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
[TBL] [Abstract][Full Text] [Related]
26. The future of cell therapies and brain repair: Parkinson's disease leads the way.
Petit GH; Olsson TT; Brundin P
Neuropathol Appl Neurobiol; 2014 Feb; 40(1):60-70. PubMed ID: 24372386
[TBL] [Abstract][Full Text] [Related]
27. Minor retinal degeneration in Parkinson's disease.
Huang YM; Yin ZQ
Med Hypotheses; 2011 Feb; 76(2):194-6. PubMed ID: 20933338
[TBL] [Abstract][Full Text] [Related]
28. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
29. [Sleep disturbances in Parkinson's disease: characteristics, evaluation and therapeutic approaches].
Faludi B; Janszky J; Komoly S; Kovács N
Orv Hetil; 2015 Jul; 156(27):1091-9. PubMed ID: 26122904
[TBL] [Abstract][Full Text] [Related]
30. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
31. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
Postuma RB; Lang AE; Gagnon JF; Pelletier A; Montplaisir JY
Brain; 2012 Jun; 135(Pt 6):1860-70. PubMed ID: 22561644
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of Parkinson's disease.
Tysnes OB; Storstein A
J Neural Transm (Vienna); 2017 Aug; 124(8):901-905. PubMed ID: 28150045
[TBL] [Abstract][Full Text] [Related]
33. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
35. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
36. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers for the diagnosis and management of Parkinson's disease.
Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
[TBL] [Abstract][Full Text] [Related]
38. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
Datta I; Bhonde R
Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease: aetiology, diagnosis, and management.
Leung H; Mok V
Hong Kong Med J; 2005 Dec; 11(6):476-89. PubMed ID: 16340025
[TBL] [Abstract][Full Text] [Related]
40. [Anaesthesia and Parkinson's disease].
Chhor V; Karachi C; Bonnet AM; Puybasset L; Lescot T
Ann Fr Anesth Reanim; 2011; 30(7-8):559-68. PubMed ID: 21530145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
